نتائج البحث - Colleen Mockbee

  • يعرض 1 - 5 نتائج من 5
تنقيح النتائج
  1. 1
    Efficacy of delayed administration of sargramostim up to 120 hours post exposure in a nonhuman primate total body radiation model

    Efficacy of delayed administration of sargramostim up to 120 hours post exposure in a nonhuman primate total body radiation model حسب Yifei Zhong, Mylène Pouliot, Anne-Marie Downey, Colleen Mockbee, Debasish Roychowdhury, W Wierzbicki, Simon Authier

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Sargramostim (rhu GM-CSF) Improves Survival of Non-Human Primates with Severe Bone Marrow Suppression after Acute, High-Dose, Whole-Body Irradiation

    Sargramostim (rhu GM-CSF) Improves Survival of Non-Human Primates with Severe Bone Marrow Suppression after Acute, High-Dose, Whole-Body Irradiation حسب Nicholas P. Clayton, Richard Khan-Malek, Charles A. Dangler, Donghui Zhang, Alexis Ascah, Malcolm Gains, Brent Gardner, Colleen Mockbee, Joan Keutzer, J McManus, Simon Authier

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer حسب Siqing Fu, Bradley R. Corr, Kerry Culm-Merdek, Colleen Mockbee, Hagop Youssoufian, Robert Stagg, R. Wendel Naumann, Robert M. Wenham, Rafael D. Rosengarten, Laura E. Benjamin, Erika Hamilton, Kathleen N. Moore

    منشور في 2022
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer

    Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer حسب Neil A. O’Brien, Dylan Conklin, Richard P. Beckmann, Tong Luo, Kevin Chau, Josh D. Thomas, Ann Mc Nulty, Christophe C. Marchal, Ondrej Kalous, Erika von Euw, Sara A. Hurvitz, Colleen Mockbee, Dennis J. Slamon

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial

    The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial حسب David Hsiehchen, Muhammad S. Beg, Radhika Kainthla, Jay Lohrey, Syed Mohammad Ali Kazmi, Leticia Khosama, Mary Claire Maxwell, Heather Kline, Courtney Katz, Asim Hassan, Naoto Kubota, E. Siglinsky, Anil K. Pillai, Hagop Youssoufian, Colleen Mockbee, Kerry Culm, Mark Uhlik, Laura E. Benjamin, Rolf A. Brekken, Chul Ahn, Amit G. Singal, Hao Zhu, Yujin Hoshida, Adam C. Yopp

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: